Background: There is currently no viable pharmaceutical therapy for COVID-19 illness that has been validated. The use of remdesivir is one of the medications for which there is no consistent evidence of a significant therapeutic benefit or a meaningful effect on survival.
Aim: The aim of this study was to determine the role of age and comorbidities on the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir at Indonesia's National Referral Hospital.
Methods: A retrospective cohort study was used in this study. The subjects in this study were confirmed clinically critical COVID-19 patients who were treated at Dr. M Djamil Hospital Padang, one of Indonesia's national referral hospitals, from January 2 to June 30, 2021. The number of sample size in this study was 90 patients. The variables of this study were divided into three independent variables (age, comorbidities, and a number of comorbidities). A dependent variable was the outcome of confirmed clinically critical COVID-19 patients. The Chi-square test was performed in bivariate analysis, and the odds ratio was calculated. SPSS version 17.0 was used to analyze the data.
Results: The results of this study found that there was an association between ages 50-59 years (OR = 10.23, 95% CI 1.89-55.53), 60-69 years (OR = 4.58, 95% CI 1.25-16.76), and > 70 years (OR = 1.91, 95% CI 1.38 -9.59), comorbid diabetes mellitus (OR = 9.78, 95% CI 1.23-77.66), the number of comorbid > 1 (OR = 10.97, 95% CI 2.19-54.96, and the number of comorbid 1 (OR = 5.69, 95% CI 1.59- 20.41) with the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir.
Conclusion: The significance of age and comorbidities on the outcome of COVID-19 patients treated with remdesivir at Indonesia's national referral hospital was confirmed in this study. This study could assist in the management of patient therapy, potentially decreasing morbidity and even patient mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885022 | PMC |
| http://dx.doi.org/10.21010/Ajidv17i1.5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The pathogenic burden potential of airborne particles in emanating from the respiratory area of COVID-19 patients (a case study).
J Occup Environ Hyg
January 2025
Air Pollution Research Center, Iran University of Medical Sciences, Tehran, Iran.
The pathogenic potential of airborne particles carrying the SARS-CoV-2 viral genome was examined by considering the size distribution of airborne particles at given distances from the respiratory zone of an infected patient after coughing or sneezing with a focus on time, temperature, and relative humidity. The results show an association between the size distribution of airborne particles, particularly PM and PM, and the presence of viral genome in different stations affected by the distance from the respiratory zone and the passage of time. The correlation with time was strong with all the dependent factors except PM.
View Article and Find Full Text PDFPrevalence of Pulmonary Embolism in COVID-19 Positive Critically Ill Children.
Crit Care Explor
January 2025
Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine/Riley Children's Health, Indianapolis, IN.
Objectives: To investigate the prevalence of pulmonary embolism (PE) in children admitted to critical care diagnosed with COVID-19 infection.
Design: Retrospective database study.
Setting: Data reported to the Virtual Pediatric Systems, 2018-2021.
Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
PLoS Med
January 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.
View Article and Find Full Text PDFThe impact of shelter-in-place during the COVID-19 pandemic on social support for mental health recovery: A prescribing-oriented qualitative study of patient perspectives.
PLoS One
January 2025
Kaiser Permanente San Jose Psychiatry, San Jose, California, United States of America.
The COVID-19 pandemic created unprecedented challenges for social connectivity and mental health, especially during mandated shelter-in-place periods. For patients engaged in mental health treatment, the social impact of their shelter-in-place experience remains an area of active investigation. This is particularly relevant in the context of social prescribing, a growing area of clinical intervention where healthcare providers actively refer patients to local social resources or activities to enhance mental health and wellbeing.
View Article and Find Full Text PDFAt what cycle threshold level are dogs able to detect SARS-CoV-2 in humans?
PLoS One
January 2025
Instituto de Biología, Universidad Nacional Autónoma de México (UNAM), México City, México.
Dogs can discriminate between people infected with SARS-CoV-2 from those uninfected, although their results vary depending on the settings in which they are exposed to infected individuals or samples of urine, sweat or saliva. This variability likely depends on the viral load of infected people, which may be closely associated with physiological changes in infected patients. Determining this viral load is challenging, and a practical approach is to use the cycle threshold (Ct) value of a RT-qPCR test.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!